JW Asset Management, LLC
JW Asset Management, LLC is an SEC-registered investment adviser that reports managing 4 hedge funds on Form ADV. It reports $476.9 million in regulatory assets under management. Its private funds, of all types, hold $476.9 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +18.9% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +66.2% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $476.9 millionForm ADV Item 5.F
- Gross assets of private funds
- $476.9 millionAll private fund types, Form ADV
- Hedge funds managed
- 44 private funds in total
- Employees
- 6Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 160805
- Latest Form ADV
- 03/20/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +47.5% | +14.8% |
| Q1 2026 | -19.4% | -4.6% |
| Q4 2025 | +46.3% | +2.4% |
| Q3 2025 | +2.2% | +7.8% |
| Q2 2025 | +7.0% | +10.4% |
| Q1 2025 | -11.5% | -4.5% |
| Q4 2024 | +3.9% | +2.1% |
| Q3 2024 | -4.9% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 29 share positions ($239,689,210) reported by JW Asset Management, LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 6, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Establishment Labs Hldgs Inc65.62%
- Sandisk Corp5.23%
- Vita Coco Co Inc5.22%
- Dell Technologies Inc3.93%
- Micron Technology Inc3.11%
- Ligand Pharmaceuticals Inc1.95%
- Sharkninja Inc1.95%
- Ralph Lauren Corp1.78%
- Idaho Strategic Resources1.65%
- Nvidia Corporation1.45%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Establishment Labs Hldgs Inc | $157,284,969 | 65.62% | 2,451,067 | -8.98% |
| Sandisk Corp | $12,544,607 | 5.23% | 7,210 | -7.68% |
| Vita Coco Co Inc | $12,517,145 | 5.22% | 218,621 | Unchanged |
| Dell Technologies Inc | $9,414,125 | 3.93% | 17,500 | +400.00% |
| Micron Technology Inc | $7,455,770 | 3.11% | 7,000 | Unchanged |
| Ligand Pharmaceuticals Inc | $4,685,550 | 1.95% | 15,000 | +275.00% |
| Sharkninja Inc | $4,683,120 | 1.95% | 26,000 | New |
| Ralph Lauren Corp | $4,260,840 | 1.78% | 12,000 | +20.00% |
| Idaho Strategic Resources | $3,953,516 | 1.65% | 141,197 | Unchanged |
| Nvidia Corporation | $3,482,795 | 1.45% | 15,250 | Unchanged |
| Five Below Inc | $2,726,620 | 1.14% | 12,418 | +24.18% |
| Cava Group Inc | $2,705,000 | 1.13% | 50,000 | Unchanged |
| Travere Therapeutics Inc | $2,649,600 | 1.11% | 45,000 | +50.00% |
| Jazz Pharmaceuticals PLC | $2,546,720 | 1.06% | 11,000 | New |
| Kiniksa Pharmaceuticals Intl | $1,641,420 | 0.68% | 22,000 | New |
| Trulieve Cannabis Corp | $914,172 | 0.38% | 83,869 | New |
| Marvell Technology Inc | $845,472 | 0.35% | 3,200 | Unchanged |
| Urogen Pharma LTD | $812,600 | 0.34% | 20,000 | New |
| Tarsus Pharmaceuticals Inc | $707,490 | 0.30% | 9,000 | New |
| Advisorshares TR | $700,600 | 0.29% | 155,000 | Unchanged |
| Eton Pharmaceuticals Inc | $689,657 | 0.29% | 13,394 | New |
| Imax Corp | $602,800 | 0.25% | 11,000 | New |
| Cinemark Hldgs Inc | $391,650 | 0.16% | 10,500 | New |
| Indivior Pharmaceuticals Inc | $358,500 | 0.15% | 10,000 | New |
| Uber Technologies Inc | $342,550 | 0.14% | 5,000 | New |
| Liquidia Corporation | $307,926 | 0.13% | 10,176 | Unchanged |
| High Tide Inc | $263,835 | 0.11% | 96,643 | Unchanged |
| Aurora Cannabis Inc | $156,000 | 0.07% | 40,000 | New |
| Heron Therapeutics Inc | $44,161 | 0.02% | 140,863 | -96.24% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 12 new positions, 4 sold out, 5 increased, 3 reduced and 9 unchanged.
Number of positions (a count, not dollars)
- New positions12
- Increased5
- Unchanged9
- Reduced3
- Sold out4
New positions
| Stock | Value | Shares |
|---|---|---|
| Sharkninja Inc | $4,683,120 | 26,000 |
| Jazz Pharmaceuticals PLC | $2,546,720 | 11,000 |
| Kiniksa Pharmaceuticals Intl | $1,641,420 | 22,000 |
| Trulieve Cannabis Corp | $914,172 | 83,869 |
| Urogen Pharma LTD | $812,600 | 20,000 |
| Tarsus Pharmaceuticals Inc | $707,490 | 9,000 |
| Eton Pharmaceuticals Inc | $689,657 | 13,394 |
| Imax Corp | $602,800 | 11,000 |
| Cinemark Hldgs Inc | $391,650 | 10,500 |
| Indivior Pharmaceuticals Inc | $358,500 | 10,000 |
| Uber Technologies Inc | $342,550 | 5,000 |
| Aurora Cannabis Inc | $156,000 | 40,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Catalyst Pharmaceuticals Inc | $12,207,161 | 388,392 |
| Iren Limited | $6,614,845 | 144,650 |
| On Hldg AG | $2,583,889 | 72,950 |
| Trulieve Cannabis Corp | $824,432 | 83,869 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Dell Technologies Inc | +14,000 | +400.00% | $9,414,125 | 17,500 |
| Ligand Pharmaceuticals Inc | +11,000 | +275.00% | $4,685,550 | 15,000 |
| Travere Therapeutics Inc | +15,000 | +50.00% | $2,649,600 | 45,000 |
| Ralph Lauren Corp | +2,000 | +20.00% | $4,260,840 | 12,000 |
| Five Below Inc | +2,418 | +24.18% | $2,726,620 | 12,418 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Establishment Labs Hldgs Inc | -241,789 | -8.98% | $157,284,969 | 2,451,067 |
| Heron Therapeutics Inc | -3,610,210 | -96.24% | $44,161 | 140,863 |
| Sandisk Corp | -600 | -7.68% | $12,544,607 | 7,210 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Establishment Labs Holdings, Inc. | 13G | 9.15% | 2,692,856 | Jul 31, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Jul 31, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Private funds reported on Form ADV (5)
As reported in the adviser's Form ADV filed Mar 22, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures